8/30/2012 8:14:12 AM
Boston-based OvaScience, which is developing infertility treatments based on stem cell science, filed documents with the SEC announcing its plans to go public. According to the filing, the company intends to sell 7.6 million shares and trade on the over-the-counter exchange. OvaScience was founded on technology developed at Harvard Medical School and Massachusetts General Hospital, which the company is using to develop a technique for rejuvenating eggs. The approach involves isolating a type of egg stem cells from the patient, injecting the mitochondria—essentially the power plants from those cells—into her eggs, and then adding sperm from the father. A human study of the technique, called Augment, will begin by the end of the year, according to the filing.
comments powered by